StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.53. The business has a fifty day simple moving average of $0.03. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.
About Nabriva Therapeutics
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- Rocket Lab is the Right Stock for the Right Time
- How to Evaluate a Stock Before Buying
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Bank Stocks – Best Bank Stocks to Invest In
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.